A report from GHTC and Policy Cures Research examines how US federal funding for global health R&D is delivering impact both abroad and at home.

Search the GHTC website

News

News

Latest news

Check out the latest news and announcements from GHTC.

USAID/Tanzania
June 20, 2025

GHTC submits FY26 appropriations testimony to Senate appropriators

GHTC sent public witness testimony to relevant Senate appropriations subcommittees urging policymakers to increase funding and include supportive policy directives for global health research and development in fiscal year 2026 (FY26) spending bills.

Read time:
GHTC sent public written testimony to the Senate Appropriations Subcommittees on State, Foreign Operations, and Related Programs (SFOPS) and Labor, Health and Human Services, Education, and Related Agencies (LHHS), urging policymakers to increase funding and include supportive policy directives for global health research and development in fiscal year 2026 (FY26) spending bills. Among other priorities, the testimony urges Congress to continue to direct the US Agency for International Development and the Department of State to prioritize science, technology, and innovation as core pillars of its global health mission and to appropriate robust funding for emerging infectious diseases and additional funding for antimicrobial resistance at the Biomedical Advanced Research and Development Authority.

Recent news

  • Sort order:

Filter by year:

Filter by category:

USAID/Tanzania
June 20, 2025

GHTC submits FY26 appropriations testimony to Senate appropriators

GHTC sent public witness testimony to relevant Senate appropriations subcommittees urging policymakers to increase funding and include supportive policy directives for global health research and development in fiscal year 2026 (FY26) spending bills.

Read time:
GHTC sent public written testimony to the Senate Appropriations Subcommittees on State, Foreign Operations, and Related Programs (SFOPS) and Labor, Health and Human Services, Education, and Related Agencies (LHHS), urging policymakers to increase funding and include supportive policy directives for global health research and development in fiscal year 2026 (FY26) spending bills. Among other priorities, the testimony urges Congress to continue to direct the US Agency for International Development and the Department of State to prioritize science, technology, and innovation as core pillars of its global health mission and to appropriate robust funding for emerging infectious diseases and additional funding for antimicrobial resistance at the Biomedical Advanced Research and Development Authority.
PATH/Matthew Dakin
June 11, 2025

GHTC signs community letter celebrating the Pandemic Agreement's adoption and calling for equity and access in implementation

GHTC signed on to Pandemic Action Network's "Working Together to Advance the Promise of the Pandemic Agreement" letter, in solidarity with 50 other nongovernmental organizations, civil society organizations, and academic institutions, celebrating the adoption of the agreement and calling on member states to continue prioritizing equity, access, and inclusivity in its implementation.

Read time: 4 minutes / External link
WHO/Christoper Black
May 27, 2025

GHTC contributes to statements delivered at WHA on the Pandemic Agreement and climate and health

GHTC contributed to statements delivered by the Global Health Council at the 78th World Health Assembly (WHA) on the Pandemic Agreement and climate change and health.

Read time:
GHTC contributed to two statements read by Global Health Council at the 78th World Health Assembly (WHA), one highlighting the need for mechanisms inclusive to civil society engagement and diligent efforts to finalize the Pathogen Access and Benefit Sharing system in the agreement's implementation and the second on climate change and health, specifically calling for the World Health Organization to commit financing for the research and development pipeline, including local, sustainable manufacturing of appropriate health and safety equipment and technology for low-resource settings.
PATH/Christopher Nelson
May 22, 2025

GHTC sends FY26 appropriations letters to US appropriators

GHTC sent letters to the relevant appropriations subcommittees in the House and Senate asking them to sustain and protect global health R&D funding in the fiscal year 2026 (FY26) budget

Read time: 45 minutes
GHTC sent letters to the relevant appropriations subcommittees in the House and Senate—the Labor, Health and Human Services, Education, and Related Agencies (LHHS); State, Foreign Operations, and Related Programs (SFOPS)/National Security, Department of State, and Related Programs (NSRP); and Defense Subcommittees on Appropriations—asking them to sustain and protect global health R&D funding in the fiscal year 2026 (FY26) budget.
WHO
May 19, 2025

Statement from the Global Health Technologies Coalition on the adoption of the Pandemic Agreement and next steps

GHTC's statement on the formal adoption of the Pandemic Agreement by the World Health Assembly.

Read time:
The Global Health Technologies Coalition (GHTC) welcomes the historic consensus on the World Health Organization (WHO) Pandemic Agreement—a first-of-its-kind instrument that, if implemented, could help reshape the global innovation ecosystem for pandemic preparedness and ensure greater equity in the development of and access to new pandemic tools. While the agreement reflects compromise and not all ambitions were met, it represents important progress and lays the groundwork for action toward global readiness and equity in future health emergencies. “There is a clear and welcome throughline in this agreement that the fruits of research and development, particularly that which is publicly funded, should and must benefit all the world’s citizens, including those in low- and middle-income countries who are far too often left behind,” said Dr. Kristie Mikus, Executive Director of GHTC. “Today, the world is sending a forceful message that we cannot and will not repeat the devastating inequities seen during the COVID-19 pandemic.”Notably, this agreement commits countries to develop policies attaching public interest conditions to public research and development (R&D) funding—an unprecedented move with the potential to transform how treatments, tests, and vaccines are developed and delivered during health crises. It also establishes a new global coordination mechanism on supply chain and logistics, requires national policies that promote post-clinical trial access to products for trial populations and at-risk groups, and outlines principles for a new Pathogen Access and Benefits Sharing (PABS) system, which would grant 20 percent of medical countermeasures produced by participating manufacturers to WHO, enabling more equitable access and distribution worldwide.It is also the first global health agreement grounded in One Health that explicitly acknowledges the interconnectedness of human, animal, and environmental health. These are historic achievements and steps in the right direction to ensure the world is better prepared to respond to future threats.“Today’s adoption is a big win for the world and for multilateralism, but the test now lies in whether countries can seal the deal with PABS and translate these promises into ratification and effective policies at the national level to drive sustained impact,” said Philip Kenol, Senior Multilateral Policy and Advocacy Officer at GHTC.GHTC calls on member states to work diligently to ensure forthcoming negotiations to finalize the PABS system bring all relevant stakeholders to the table and achieve an agreement that drives innovation and delivers equitable access for all who need it, especially underserved populations. Countries must maintain the momentum to ensure that universal ratification of these important obligations and principles catalyzes a stronger and more effective pandemic preparedness architecture that benefits everyone, everywhere.